Allied Market Research
Loading...
Cart
0

Oral Antibiotics Market Expected to Reach $23,306.10 million by 2027—Allied Market Research

 

quote the use of oral antibiotics is gaining popularity, owing to its ease of use and convenience for patients. In addition, rise in consumption of antibiotics in low and middle-income countries (LMICs), increase in prevalence of infectious diseases, development of novel approaches for new antibiotics to treat bacterial infections, and large number of clinical trials are projected to drive the oral antibiotics market growth during the forecast period. Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, owing to rise in antimicrobial resistance, which leads pharmaceutical companies toward R&D for next generation antibiotics. quote

Onkar Sumant
Assistant Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, “oral antibiotics market by class (beta lactam & beta lactamase inhibitors, quinolones, macrolide, and others), application (community-acquired respiratory tract infections (CARTIS), urinary tract infections (UTIS), dental, others), drug origin (natural, semisynthetic, synthetic), spectrum of activity (broad-spectrum antibiotic, mid/narrow-spectrum antibiotic), drug type (branded and generics): global opportunity analysis and industry forecast, 2019–2027,” the global oral antibiotics market was valued at $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, registering a CAGR of 2.7% from 2019 to 2027.

Antibiotics serve a useful therapeutic purpose for the treatment and control of pathogens. The medications are used to either inhibit or prevent bacterial infections referred as bactericidal and bacteriostatic antibiotics, respectively. Various types of antibiotics such as penicillin, cephalosporin, carbapenem, and monobactam are available in pharmacies and hospitals that are used to treat infectious diseases. However, the antibiotic resistance is a global problem and it is considered as a threat, owing to its effect on morbidity and mortality. The treatment with the help of oral antibiotics has the potential to reduce prolonged hospital stay, treatment cost, and further complications. Oral drug delivery continues to rise in popularity as key players are focused on extending R&D efforts, thereby improving patient convenience. 

The economies across the world are suffering from the impact of COVID-19 and many industries are experiencing losses. However, pharmaceutical companies have a center stage in the COVID-19 fight and are responding to rapid challenges. Whereas, the Covid-19 pandemic has impacted moderately on oral antibiotics market, as the coronavirus damages cells so badly that it becomes easier for certain bacteria to cause secondary infections. For instance, bacterial pneumonia in influenza patients, which can be treated with antibiotics. Hence, the macrolide antibiotics such as azithromycin, erythromycin, clarithromycin, and spiramycin are prescribing for the treatment of secondary infections.

The oral antibiotics market is expected to exhibit significant growth during the forecast period, owing to factors such as increased consumption in low and middle-income countries (LMICs) and rise in prevalence of infectious diseases along with imbalance of supply-demand of antibiotics. In addition, rise in R&D efforts undertaken by key players operating in the market for development of advanced oral antibiotics to treat bacterial infections and carry out a large number of clinical trials further supplements the market growth. In addition, use of novel approaches for development of new oral antibiotics for treating bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and the time taken for regulatory approvals are projected to hamper the market growth. Furthermore, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant opportunities for the market players. 

The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications such as acute respiratory distress syndrome, usually as a result of pneumonia. In the pandemic situation antibiotics are considered to have an important part in the disease treatment. COVID-19 has led to increase in the bacterial infections, as antibiotics are prescribed to prevent secondary infections following an antiviral immune response. Various antibiotics therapies have also been commonly used to support COVID19 treatments globally, which drives the use of oral antibiotics as the first line of treatment. 

Based on class, the beta lactam & beta lactamase inhibitors segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period due to its spectrum of activity. These antibiotics are a class of broad-spectrum antibiotics. A broad-spectrum antibiotic acts against both Gram-positive & Gram-negative bacteria and effective on the infections with multiple groups of bacteria. Thus, the demand for beta lactam & beta lactamase inhibitors antibiotics is high. On the other side, the demand for quinolones is projected to exhibit the fastest market growth during the forecast period owing to the rise in demand of broad-spectrum bactericidal activity new generation quinolones, excellent oral bioavailability, good tissue penetration, and better safety & tolerability.

Depending on drug origin, the semisynthetic dominates the market in 2018, and is expected to remain dominant during the forecast period. This is attributed to the fact that the semisynthetic antibiotics have improved coverage and effectiveness against a wide range of organisms. Also, the semisynthetic antibiotics can be administered orally and its less costly to administer than other antibiotics in some cases.

Key Findings Of The Study

  • By class, the beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018.

  • On the basis of spectrum of activity, the broad-spectrum segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 3.3% from 2019 to 2027.

  • Depending on application, the community-respiratory tract infections segment is expected to exhibit the highest CAGR during the forecast period.

  • By drug origin, the semisynthetic segment was the major revenue contributor in 2018.

  • By drug type, the branded segment accounted for largest revenue in 2018, and is expected to be dominant during the forecast period.

  • LAMEA is estimated to grow at a CAGR of 3.3% during the forecast period.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Oral Antibiotics Market, by Class (Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others), Application (Community-Acquired Respiratory Tract Infections (CARTIS), Urinary Tract Infections (UTIS), Dental, and Others), Drug Origin (Natural, Semisynthetic, Synthetic), Spectrum Of Activity (Broad-Spectrum Antibiotic, Mid/Narrow-Spectrum Antibiotic), Drug Type (Branded And Generics): Global Opportunity Analysis and Industry Forecast, 2020–2027 quote

View Report
 
 
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Oral Antibiotics Market"
Purchase Enquiry